Trending...
- 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
- New Book, The KI of Marketing, Helps Small Businesses Grow Without Trying to Outspend Bigger Competitors
- Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
CHAPEL HILL, N.C., June 21, 2024 ~ The International Society on Thrombosis and Haemostasis (ISTH) has recently released a groundbreaking clinical practice guideline for the treatment of congenital hemophilia A and B. This guideline, developed over several years by a multidisciplinary panel of physicians and patient representatives from around the world, utilizes strict GRADE methodology to provide a rigorous and structured decision-making framework for clinicians, healthcare professionals, patients, and their caregivers.
Hemophilia is a rare bleeding disorder caused by deficiencies in blood coagulation factors. It affects hundreds of thousands of individuals worldwide and requires complex management strategies. The objective of this guideline is to offer a comprehensive overview of evidence to help inform treatment decisions.
The panel prioritized key clinical questions and outcomes crucial for both clinicians and patients. The recommendations underwent rigorous analyses, including public commentary, to ensure comprehensiveness, transparency, and inclusivity. The result is a set of 13 recommendations addressing critical aspects of hemophilia A and B care.
More on ncarol.com
One of the most significant recommendations advocates for prophylactic treatment over episodic interventions for severe and moderately severe hemophilia A and B. This marks a paradigm shift in clinical practice as it emphasizes the importance of preventing bleeds rather than treating them after they occur.
Dr. Suely M. Rezende, Chair of the ISTH Hemophilia Guideline Panel, stated that "with hemophilia management being complex, our guideline provides clarity, guiding treatment decisions with evidence-based insight while highlighting the importance of considering individual risks, values, and preferences."
To provide further guidance on the interpretation and implementation of the guideline, commentaries have been published alongside it by preeminent experts in the field. These commentaries also address challenges for clinical practice and policy related to hemophilia treatment.
More on ncarol.com
The new guideline also addresses important gaps in scientific data and identifies critical research priorities. As new treatments become available in the ever-evolving landscape of hemophilia care, future updates to the guideline are expected to encompass these advancements.
The ISTH remains committed to advancing hemophilia research and improving the lives of people with hemophilia worldwide. By continuously updating and complementing this guideline, they aim to drive innovation and enhance outcomes for individuals living with this rare disease.
For more information and to access the full guideline and accompanying commentaries, please visit https://www.isth.org/page/hemophiliaguideline. This comprehensive resource provides valuable insights into the evolving hemophilia treatment landscape and emphasizes the importance of patient involvement and shared decision-making in treatment decisions.
Hemophilia is a rare bleeding disorder caused by deficiencies in blood coagulation factors. It affects hundreds of thousands of individuals worldwide and requires complex management strategies. The objective of this guideline is to offer a comprehensive overview of evidence to help inform treatment decisions.
The panel prioritized key clinical questions and outcomes crucial for both clinicians and patients. The recommendations underwent rigorous analyses, including public commentary, to ensure comprehensiveness, transparency, and inclusivity. The result is a set of 13 recommendations addressing critical aspects of hemophilia A and B care.
More on ncarol.com
- Kentucky's Plane Crash Data Lands Far from the State's Busiest Airports
- StockResearch AI Initiates Coverage on Apple (AAPL) With New Report Examining Valuation, AI Strategy and Future Growth
- Netberg Announces the Aurora X2 Switch Series, Built on Xsight Labs' Programmable X2 Silicon
- Pete Verbica: America Needs Statesmanship and Common Sense — Not a Cult of Personality
- Heidi G. Villari of The Villari Firm, PLLC Recognized in The Best Lawyers in America 2027 for Construction Law and Personal Injury Litigation
One of the most significant recommendations advocates for prophylactic treatment over episodic interventions for severe and moderately severe hemophilia A and B. This marks a paradigm shift in clinical practice as it emphasizes the importance of preventing bleeds rather than treating them after they occur.
Dr. Suely M. Rezende, Chair of the ISTH Hemophilia Guideline Panel, stated that "with hemophilia management being complex, our guideline provides clarity, guiding treatment decisions with evidence-based insight while highlighting the importance of considering individual risks, values, and preferences."
To provide further guidance on the interpretation and implementation of the guideline, commentaries have been published alongside it by preeminent experts in the field. These commentaries also address challenges for clinical practice and policy related to hemophilia treatment.
More on ncarol.com
- When the Coroner's Report Isn't Enough: Colorado Families Turn to Private Autopsy for Closure
- Belmont, NC Emerges as More Than a Charlotte Alternative for Homebuyers
- Nearly One-Third of CRE Asset Managers Make Major Capital Decisions on Gut Instinct, New Survey Finds
- RemoteBridge Names Dr. John N. Just, Ed.D. Chief Executive Officer
- Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History
The new guideline also addresses important gaps in scientific data and identifies critical research priorities. As new treatments become available in the ever-evolving landscape of hemophilia care, future updates to the guideline are expected to encompass these advancements.
The ISTH remains committed to advancing hemophilia research and improving the lives of people with hemophilia worldwide. By continuously updating and complementing this guideline, they aim to drive innovation and enhance outcomes for individuals living with this rare disease.
For more information and to access the full guideline and accompanying commentaries, please visit https://www.isth.org/page/hemophiliaguideline. This comprehensive resource provides valuable insights into the evolving hemophilia treatment landscape and emphasizes the importance of patient involvement and shared decision-making in treatment decisions.
0 Comments
Latest on ncarol.com
- LCC Asia Pacific Sponsors CubeSatPlus 2026 at UNSW Sydney
- The Sharon at SouthPark Breaks Ground on $178 Million Expansion
- Pattern Recognition In The Arts
- Real Estate Syndication Attorney Tilden Moschetti Releases The Real Estate Private Equity Blueprint
- 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate
- Couture Master Perfumer JoAnne Bassett Unveils All-Natural Parfum in Oil Collection in Gift Box
- Independent Colbert Packaging Thrives Amid Industrywide Consolidation
- Free Commercial Glass Estimating and Code Compliance Tools Launched by Landmark Construction - The Leading Glass Company in Los Angeles
- Tallahassee Million-Dollar Home Sales Rise in 2026 as Median Selling Time More Than Doubles
- STEM For Kids® Unveil Turn-Key "Screen-Smart" Solution to Bridge Teacher Preparedness Gaps in Texas
- Award-Winning Couture Master Perfumer JoAnne Bassett Launches All-Natural DIY Perfume Making Kits
- Couture Master Perfumer JoAnne Bassett Offers Rare Opportunity to Acquire 70 Formula Perfume Codex
- Slotozilla Reports Strong Growth in Q2 2026
- Flexible Plan Investments Names Carl Resnick President
- Paula Josephine Sadler Releases "Imagine" on 24th Anniversary of Sobriety
- Ritz-Carlton Residences Houston Generates Strong Early New Construction Sales at 2120 Post Oak Blvd
- No Sugar Baker Continues National Growth with Seattle Market Expansion Across Washington, Idaho, and Alaska
- The Refugee Archive Launches Campaign to Preserve 21 Female-Headed Household Oral Histories in Rebel-Controlled Goma
- Space Ambitions Expanding as New Testing Builds on NASA Results and Targets MEO, GEO and Next-Generation Orbital Markets: Ascent Solar Technologies
- FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)